<article article-type="case-report" dtd-version="1.4" xml:lang="en"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cureus</journal-id><journal-id journal-id-type="iso-abbrev">Cureus</journal-id><journal-id journal-id-type="pmc-domain-id">2757</journal-id><journal-id journal-id-type="pmc-domain">cureus</journal-id><journal-title-group><journal-title>Cureus</journal-title></journal-title-group><issn pub-type="epub">2168-8184</issn><publisher><publisher-name>Cureus Inc.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12828242</article-id><article-id pub-id-type="pmcid-ver">PMC12828242.1</article-id><article-id pub-id-type="pmcaid">12828242</article-id><article-id pub-id-type="pmcaiid">12828242</article-id><article-id pub-id-type="pmid">41583258</article-id><article-id pub-id-type="doi">10.7759/cureus.99972</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Internal Medicine</subject></subj-group><subj-group><subject>Allergy/Immunology</subject></subj-group><subj-group><subject>Gastroenterology</subject></subj-group></article-categories><title-group><article-title>Ketamine-Induced Cholangiopathy With Concomitant Hemorrhagic Cystitis: An Emerging and Underrecognized Cause of Cholestasis</article-title></title-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Muacevic</surname><given-names initials="A">Alexander</given-names></name></contrib><contrib contrib-type="editor"><name name-style="western"><surname>Adler</surname><given-names initials="JR">John R</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Nazir</surname><given-names initials="K">Kamran</given-names></name><xref ref-type="aff" rid="aff-1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Ahmed</surname><given-names initials="W">Waqas</given-names></name><xref ref-type="aff" rid="aff-2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rafi</surname><given-names initials="S">Salman</given-names></name><xref ref-type="aff" rid="aff-3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ahmad</surname><given-names initials="A">Adeel</given-names></name><xref ref-type="aff" rid="aff-1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Khaleeq</surname><given-names initials="A">Asim</given-names></name><xref ref-type="aff" rid="aff-4">4</xref></contrib></contrib-group><aff id="aff-1">
<label>1</label>
Medicine, Lancashire Teaching Hospitals NHS Foundation Trust, Chorley, GBR </aff><aff id="aff-2">
<label>2</label>
Respiratory Medicine, Lancashire Teaching Hospitals NHS Foundation Trust, Chorley, GBR </aff><aff id="aff-3">
<label>3</label>
Cardiology, Lancashire Teaching Hospitals NHS Foundation Trust, Chorley, GBR </aff><aff id="aff-4">
<label>4</label>
Internal Medicine, Kettering General Hospital NHS Foundation Trust, Kettering, GBR </aff><author-notes><corresp id="cor1">
Waqas Ahmed <email>drwikki@yahoo.com</email>
</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>23</day><month>12</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><month>12</month><year>2025</year></pub-date><volume>17</volume><issue>12</issue><issue-id pub-id-type="pmc-issue-id">501569</issue-id><elocation-id>e99972</elocation-id><history><date date-type="accepted"><day>23</day><month>12</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>23</day><month>12</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>24</day><month>01</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-01-26 15:25:12.620"><day>26</day><month>01</month><year>2026</year></date></event></pub-history><permissions><copyright-statement>Copyright © 2025, Nazir et al.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Nazir et al.</copyright-holder><license><ali:license_ref content-type="ccbylicense" specific-use="textmining" xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="cureus-0017-00000099972.pdf" xmlns:xlink="http://www.w3.org/1999/xlink"/><self-uri xlink:href="https://cureus.com/articles/434123-ketamine-induced-cholangiopathy-with-concomitant-hemorrhagic-cystitis-an-emerging-and-underrecognized-cause-of-cholestasis" xmlns:xlink="http://www.w3.org/1999/xlink">This article is available from https://cureus.com/articles/434123-ketamine-induced-cholangiopathy-with-concomitant-hemorrhagic-cystitis-an-emerging-and-underrecognized-cause-of-cholestasis</self-uri><abstract><p>Ketamine-induced cholangiopathy (KIC) is a rare but increasingly recognized manifestation of chronic ketamine toxicity, often accompanied by urinary tract injury such as hemorrhagic cystitis. We report the case of a 55-year-old female with recurrent hemorrhagic cystitis and a long-standing history of intermittent recreational ketamine use who presented with asymptomatic cholestatic liver enzyme abnormalities. Hepatobiliary ultrasound revealed hepatic steatosis without ductal dilatation, and magnetic resonance cholangiopancreatography demonstrated multifocal biliary stricturing with a beaded appearance of the intrahepatic bile ducts. Serological testing for autoimmune and infectious etiologies was negative. Cystoscopy revealed inflammatory bladder changes, and histopathology confirmed ketamine-induced hemorrhagic cystitis. Following cessation of ketamine use, the patient demonstrated biochemical improvement. This case emphasizes the multisystem toxic potential of ketamine, highlighting the importance of recognizing KIC with concomitant hemorrhagic cystitis as an emerging cause of cholestasis and urinary tract injury.</p></abstract><kwd-group kwd-group-type="author"><kwd>biliary stricture</kwd><kwd>hepatobiliary complication</kwd><kwd>ketamine-induced cholangiopathy</kwd><kwd>ketamine-induced cystitis</kwd><kwd>recurrent hemorrhagic cystitis</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Ketamine, synthesized in the early 1960s, is a phencyclidine derivative that functions as a dissociative anesthetic through potent antagonism of N-methyl-D-aspartate (NMDA) receptors [<xref ref-type="bibr" rid="REF1">1</xref>]. Clinically, it has been widely utilized for anesthesia and analgesia owing to its rapid onset, profound pain control, and hemodynamic stability. Ketamine undergoes extensive hepatic metabolism via cytochrome P450 enzymes, predominantly CYP2B6 and CYP3A4, to form nor-ketamine, which is excreted mainly through the kidneys (≈90%) and, to a lesser extent, via bile (≈10%) [<xref ref-type="bibr" rid="REF2">2</xref>]. These pharmacologic properties make ketamine highly effective in clinical practice but also create pathways for toxicity when used in excess.</p><p>Despite its therapeutic value, increasing recreational use has revealed significant hepatobiliary and urinary complications [<xref ref-type="bibr" rid="REF3">3</xref>,<xref ref-type="bibr" rid="REF4">4</xref>]. This trend is clinically important, as many affected patients present first to general medical or emergency settings. The precise pathogenesis of ketamine-induced liver injury remains uncertain, though proposed mechanisms include NMDA receptor-mediated smooth muscle relaxation of bile ducts leading to ductal dilatation and cholestasis [<xref ref-type="bibr" rid="REF5">5</xref>], direct epithelial toxicity from ketamine metabolites [<xref ref-type="bibr" rid="REF6">6</xref>], and vagally mediated reductions in gallbladder motility causing bile stasis [<xref ref-type="bibr" rid="REF7">7</xref>]. Together, these mechanisms may contribute to a progressive cholangiopathy in chronic users.</p><p>Chronic ketamine abuse, typically over a median duration of 24 months [<xref ref-type="bibr" rid="REF8">8</xref>], has been associated with cholangiopathy resembling primary sclerosing cholangitis (PSC). Acute ketamine exposure may lead to drug-induced liver injury [<xref ref-type="bibr" rid="REF9">9</xref>], whereas prolonged or heavy use more often results in cholangiopathy [<xref ref-type="bibr" rid="REF10">10</xref>,<xref ref-type="bibr" rid="REF11">11</xref>], manifesting with abdominal pain, jaundice, and cholestatic liver enzyme abnormalities [<xref ref-type="bibr" rid="REF12">12</xref>]. Magnetic resonance cholangiopancreatography (MRCP) often demonstrates multifocal intrahepatic and extrahepatic ductal strictures and dilatations, consistent with ketamine-induced cholangiopathy (KIC) [<xref ref-type="bibr" rid="REF9">9</xref>].</p><p>This case highlights an increasingly recognized but still underdiagnosed complication of recreational ketamine use, underscoring the need for clinicians to consider ketamine-associated cholangiopathy in patients presenting with unexplained cholestasis.</p></sec><sec sec-type="cases"><title>Case presentation</title><p>A 55-year-old physically active and independent woman (Performance Status 1), with no history of smoking and only occasional social alcohol consumption, was referred by her general practitioner in January 2025 for evaluation of persistently elevated cholestatic liver function tests (LFTs) over the preceding six months. Her past medical history was notable for well-controlled hypertension and recurrent episodes of hemorrhagic cystitis, for which she was under ongoing urological follow-up.</p><p>On clinical assessment, she appeared well and remained entirely asymptomatic. A comprehensive systemic review was unremarkable, and both abdominal and hepatic examinations revealed no abnormalities. The primary objective was to identify the underlying cause of the persistently deranged cholestatic LFTs.</p><p>Initial biochemical investigations demonstrated chronically elevated alkaline phosphatase (ALP 750 U/L) and gamma-glutamyl transferase (GGT 1250 U/L), which had persisted for more than six months without diagnostic clarification. The detailed LFT profile is presented in Table <xref ref-type="table" rid="TAB1">1</xref>. Noninvasive liver screening, including viral (HAV, HBV, HCV, HEV, and HIV), autoimmune (antinuclear antibodies (ANA), antineutrophil cytoplasmic antibodies (ANCA), and IgG4), and metabolic (iron studies, ceruloplasmin, and alpha-1 antitrypsin) panels, yielded no abnormalities (Table <xref ref-type="table" rid="TAB2">2</xref>). Abdominal ultrasonography was unremarkable except for mild hepatic steatosis. Further evaluation to exclude secondary causes of sclerosing cholangitis, including HIV serology, IgG4 levels, autoimmune markers, and tumor markers (CA 19-9), demonstrated no significant findings (Table <xref ref-type="table" rid="TAB3">3</xref>).</p><table-wrap id="TAB1" orientation="portrait" position="float"><label>Table 1</label><caption><title>LFTs</title><p>Markedly elevated ALP and GGT suggest a cholestatic pattern, likely due to an obstructive biliary cause such as a stone, stricture, or tumor.</p><p>ALP, alkaline phosphatase; ALT, alanine aminotransferase; GGT, gamma-glutamyl transferase; LFTs, liver function tests</p></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td colspan="1" rowspan="1">
LFTs
</td><td colspan="1" rowspan="1">
Patient’s results
</td><td colspan="1" rowspan="1">
Reference range
</td></tr><tr><td colspan="1" rowspan="1">
Bilirubin
</td><td colspan="1" rowspan="1">
&lt;5
</td><td colspan="1" rowspan="1">
3-21 µmol/L
</td></tr><tr style="background-color:#ccc"><td colspan="1" rowspan="1">
ALP
</td><td colspan="1" rowspan="1">
673
</td><td colspan="1" rowspan="1">
40-129 IU/L
</td></tr><tr><td colspan="1" rowspan="1">
GGT
</td><td colspan="1" rowspan="1">
1295
</td><td colspan="1" rowspan="1">
10-60 IU/L
</td></tr><tr style="background-color:#ccc"><td colspan="1" rowspan="1">
ALT
</td><td colspan="1" rowspan="1">
171
</td><td colspan="1" rowspan="1">
10-45 IU/L
</td></tr><tr><td colspan="1" rowspan="1">
Albumin
</td><td colspan="1" rowspan="1">
45
</td><td colspan="1" rowspan="1">
35-50 g/L
</td></tr></tbody></table></table-wrap><table-wrap id="TAB2" orientation="portrait" position="float"><label>Table 2</label><caption><title>Noninvasive liver screening</title><p>Unremarkable noninvasive liver screening excludes viral hepatitis, autoimmune hepatitis, hereditary hemochromatosis, Wilson disease, alpha-1 antitrypsin deficiency, or primary biliary cholangitis.</p><p>Anti-HAV Ab, anti-hepatitis A virus antibody; Anti-HCV Ab, anti-hepatitis C virus antibody; Anti-HEV Ab, anti-hepatitis E virus antibody; HBsAg, hepatitis B surface antigen; S/CO, signal-to-cutoff ratio</p></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td colspan="1" rowspan="1">Noninvasive liver screening</td><td colspan="1" rowspan="1">Patient’s results</td><td colspan="1" rowspan="1">Reference ranges</td></tr><tr><td colspan="1" rowspan="1">Anti-HAV Ab</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Negative (S/CO &lt; assay cutoff)</td></tr><tr style="background-color:#ccc"><td colspan="1" rowspan="1">HBsAg</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Negative (S/CO &lt; assay cutoff)</td></tr><tr><td colspan="1" rowspan="1">Anti-HCV Ab</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Negative (S/CO &lt; assay cutoff)</td></tr><tr style="background-color:#ccc"><td colspan="1" rowspan="1">Anti-HEV Ab</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Negative (S/CO &lt; assay cutoff)</td></tr><tr><td colspan="1" rowspan="1">Autoimmune screening</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Negative (S/CO &lt; assay cutoff)</td></tr><tr style="background-color:#ccc"><td colspan="1" rowspan="1">Serum ferritin</td><td colspan="1" rowspan="1">51</td><td colspan="1" rowspan="1">15-150 µg/L</td></tr><tr><td colspan="1" rowspan="1">Iron saturation</td><td colspan="1" rowspan="1">24</td><td colspan="1" rowspan="1">20-50%</td></tr><tr style="background-color:#ccc"><td colspan="1" rowspan="1">IgA</td><td colspan="1" rowspan="1">2.1</td><td colspan="1" rowspan="1">0.7-4.0 g/L</td></tr><tr><td colspan="1" rowspan="1">IgM</td><td colspan="1" rowspan="1">0.8</td><td colspan="1" rowspan="1">0.4-2.3 g/L</td></tr><tr style="background-color:#ccc"><td colspan="1" rowspan="1">IgG</td><td colspan="1" rowspan="1">11.9</td><td colspan="1" rowspan="1">7-16 g/L</td></tr><tr><td colspan="1" rowspan="1">Alpha-1 antitrypsin level</td><td colspan="1" rowspan="1">1.5</td><td colspan="1" rowspan="1">1.0-2.0 g/L</td></tr></tbody></table></table-wrap><table-wrap id="TAB3" orientation="portrait" position="float"><label>Table 3</label><caption><title>Primary and secondary sclerosing cholangitis screening tests</title><p>Unremarkable PSC (negative ANA, ANCA, and no evidence of IBD) and negative secondary sclerosing cholangitis, including infections (HIV and Ascaris), autoimmune cholangitis (negative IgG4), or sinister pathology such as cholangiocarcinoma.</p><p>ANA: Negative - no autoimmune connective tissue disease; Positive - may indicate autoimmune disorders depending on titer and pattern. ANCA: Negative - no ANCA-associated vasculitis; Positive - may suggest vasculitic disease depending on ANCA type and titer.</p><p>ANA, antinuclear antibodies; ANCA, antineutrophil cytoplasmic antibodies; CA 19-9, carbohydrate antigen 19-9; IBD, inflammatory bowel disease; PSC, primary sclerosing cholangitis; S/CO, signal-to-cutoff ratio</p></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td colspan="1" rowspan="1">Primary and secondary sclerosing cholangitis screening</td><td colspan="1" rowspan="1">Patient’s results</td><td colspan="1" rowspan="1">Reference range</td></tr><tr><td colspan="1" rowspan="1">HIV serology</td><td colspan="1" rowspan="1">Nonreactive</td><td colspan="1" rowspan="1">Reactive/nonreactive (S/CO ratio)</td></tr><tr style="background-color:#ccc"><td colspan="1" rowspan="1">IgG4 antibodies</td><td colspan="1" rowspan="1">1.26</td><td colspan="1" rowspan="1">0.03-2.01 g/L</td></tr><tr><td colspan="1" rowspan="1">ANA</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Negative</td></tr><tr style="background-color:#ccc"><td colspan="1" rowspan="1">ANCA</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">CA 19-9</td><td colspan="1" rowspan="1">13</td><td colspan="1" rowspan="1">0-37 U/mL</td></tr></tbody></table></table-wrap><p>Fibrosis assessment showed a FIB-4 score of 1.4, and transient elastography (FibroScan; Table <xref ref-type="table" rid="TAB4">4</xref>) revealed a liver stiffness measurement (LSM) of 6.4 kPa and a controlled attenuation parameter of 310 dB/m, consistent with mild hepatic steatosis and no significant fibrosis.</p><table-wrap id="TAB4" orientation="portrait" position="float"><label>Table 4</label><caption><title>FibroScan</title><p>LSM &lt;7 kPa is consistent with F0-F1 fibrosis, indicating mild fibrosis and effectively ruling out advanced fibrosis or cirrhosis.</p><p>AUROC, area under the receiver operating characteristic; CAP, controlled attenuation parameter; LSM, liver stiffness measurement</p></caption><table frame="hsides" rules="groups"><tbody><tr style="background-color:#ccc"><td colspan="1" rowspan="1">
FibroScan parameters
</td><td colspan="1" rowspan="1">
Patient’s results
</td><td colspan="1" rowspan="1">
Units
</td><td colspan="1" rowspan="1">
Reference range
</td></tr><tr><td colspan="1" rowspan="1">
LSM
</td><td colspan="1" rowspan="1">
6.4
</td><td colspan="1" rowspan="1">
kPa
</td><td colspan="1" rowspan="1">
&lt;7 kPa: F0/F1 fibrosis; 7-8 kPa: F2 fibrosis; 10-12 kPa: F3 fibrosis; &gt;12 kPa: cACLD (F3/F4); &gt;14 kPa: cirrhosis (F4)
</td></tr><tr style="background-color:#ccc"><td colspan="1" rowspan="1">
CAP
</td><td colspan="1" rowspan="1">
310
</td><td colspan="1" rowspan="1">
dB/m
</td><td colspan="1" rowspan="1">
&lt;238: normal; 238-260: mild steatosis; 260-290: moderate steatosis; &gt;290: severe steatosis
</td></tr><tr><td colspan="1" rowspan="1">
AUROC
</td><td colspan="1" rowspan="1">
0.81
</td><td colspan="1" rowspan="1">
0-1
</td><td colspan="1" rowspan="1">
0.8-0.99
</td></tr></tbody></table></table-wrap><p>MRCP demonstrated multifocal stricturing and a characteristic “beaded” appearance of the intrahepatic bile ducts, findings suggestive of either PSC or a secondary sclerosing process, notably KIC. Representative MRCP images illustrating these features are shown in Figure <xref ref-type="fig" rid="FIG1">1</xref>, Figure <xref ref-type="fig" rid="FIG2">2</xref>, and Figure <xref ref-type="fig" rid="FIG3">3</xref>. A comprehensive diagnostic workup to rule out other etiologies for secondary sclerosing cholangitis, including HIV serology, ANCA, ANA, IgG4 subclass, and tumor marker CA 19-9, was entirely negative. The systematic approach used to exclude alternative causes of secondary sclerosing cholangitis is summarized in Figure <xref ref-type="fig" rid="FIG4">4</xref>.</p><fig fig-type="figure" id="FIG1" orientation="portrait" position="anchor"><label>Figure 1</label><caption><title>MRCP image demonstrating multifocal intrahepatic biliary strictures with a classic “beaded” appearance (arrows)</title><p>These alternating narrowings and dilatations are characteristic of cholangiopathy and raise suspicion for ketamine-related biliary injury.</p><p>MRCP, magnetic resonance cholangiopancreatography</p></caption><graphic orientation="portrait" position="float" xlink:href="cureus-0017-00000099972-i01.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig><fig fig-type="figure" id="FIG2" orientation="portrait" position="anchor"><label>Figure 2</label><caption><title>MRCP image highlighting pronounced central biliary stenosis (arrows), predominantly affecting the proximal intrahepatic ducts</title><p>The smooth tapering pattern helps differentiate drug-induced cholangiopathy from inflammatory causes such as PSC.</p><p>MRCP, magnetic resonance cholangiopancreatography; PSC, primary sclerosing cholangitis</p></caption><graphic orientation="portrait" position="float" xlink:href="cureus-0017-00000099972-i02.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig><fig fig-type="figure" id="FIG3" orientation="portrait" position="anchor"><label>Figure 3</label><caption><title>MRCP image showing segmental stricturing of the intrahepatic bile ducts (arrows), with focal areas of narrowing interspersed with normal-caliber ducts</title><p>These findings support multifocal biliary involvement consistent with KIC.</p><p>KIC, ketamine-induced cholangiopathy; MRCP, magnetic resonance cholangiopancreatography</p></caption><graphic orientation="portrait" position="float" xlink:href="cureus-0017-00000099972-i03.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig><fig fig-type="figure" id="FIG4" orientation="portrait" position="anchor"><label>Figure 4</label><caption><title>Beaded appearance of bile duct - primary and secondary sclerosing cholangitis screening tests</title><p>ANCA, antineutrophil cytoplasmic antibodies; ANA, antinuclear antibodies; IBD, inflammatory bowel disease; MRCP, magnetic resonance cholangiopancreatography</p><p>Image credit: Kamran Nazir</p></caption><graphic orientation="portrait" position="float" xlink:href="cureus-0017-00000099972-i04.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig><p>Concurrent urological evaluation for recurrent hemorrhagic cystitis revealed chronic inflammatory changes on cystoscopy and bladder biopsy, consistent with ketamine-associated cystitis. A CT scan of the pelvis demonstrated diffuse bladder wall thickening, as shown in Figure <xref ref-type="fig" rid="FIG5">5</xref>. Correlating these findings with her confirmed decade-long history of intermittent ketamine use and the exclusion of alternative hepatobiliary causes established the diagnosis of KIC, a form of secondary sclerosing cholangitis.</p><fig fig-type="figure" id="FIG5" orientation="portrait" position="anchor"><label>Figure 5</label><caption><title>Axial CT scan of the pelvis demonstrating circumferential bladder wall thickening (arrow), a radiological feature suggestive of chronic inflammatory changes associated with ketamine-induced hemorrhagic cystitis</title></caption><graphic orientation="portrait" position="float" xlink:href="cureus-0017-00000099972-i05.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig><p>The case was discussed at a hepato-pancreato-biliary multidisciplinary team (MDT) meeting, where consensus supported the diagnosis of ketamine-induced secondary sclerosing cholangitis. The MDT recommended strict abstinence from ketamine to prevent further hepatic injury and disease progression, annual follow-up with MRCP to monitor biliary stricturing and hepatic fibrosis, and referral to mental health services for support with abstinence and management of underlying psychosocial factors contributing to ketamine use. The patient was also placed under ongoing multidisciplinary surveillance, integrating hepatology, urology, and psychological care to manage potential hepatobiliary and urological complications and optimize long-term outcomes.</p></sec><sec sec-type="discussion"><title>Discussion</title><p>KIC is an increasingly recognized but still underdiagnosed form of secondary sclerosing cholangitis, predominantly reported in individuals with chronic recreational ketamine use [<xref ref-type="bibr" rid="REF3">3</xref>,<xref ref-type="bibr" rid="REF10">10</xref>,<xref ref-type="bibr" rid="REF12">12</xref>]. Consistent with previously published case series and systematic reviews, our patient demonstrated a predominantly cholestatic biochemical profile with markedly elevated ALP and GGT, preserved synthetic liver function, and characteristic MRCP findings of multifocal biliary stricturing with a beaded appearance [<xref ref-type="bibr" rid="REF9">9</xref>,<xref ref-type="bibr" rid="REF10">10</xref>,<xref ref-type="bibr" rid="REF12">12</xref>].</p><p>The radiological resemblance between KIC and PSC represents a major diagnostic challenge. Prior studies have shown that KIC often exhibits smoother, less irregular strictures compared to the classic “pruned-tree” appearance seen in advanced PSC [<xref ref-type="bibr" rid="REF10">10</xref>,<xref ref-type="bibr" rid="REF12">12</xref>]. Consistent with this, MRCP in our patient demonstrated mild, smooth intrahepatic stricturing without significant ductal irregularity or advanced fibrosis, supporting a drug-induced rather than autoimmune etiology.</p><p>In contrast to PSC, which is strongly associated with inflammatory bowel disease in up to 70-80% of cases, our patient had no gastrointestinal symptoms, no history of IBD, and negative autoimmune serology, including ANA and ANCA [<xref ref-type="bibr" rid="REF10">10</xref>,<xref ref-type="bibr" rid="REF12">12</xref>]. These findings mirror those reported in ketamine-related cholangiopathy case series, where autoimmune markers are typically absent, and IgG4 levels remain within normal limits [<xref ref-type="bibr" rid="REF6">6</xref>,<xref ref-type="bibr" rid="REF10">10</xref>].</p><p>An important distinguishing feature in our case was the coexistence of ketamine-induced hemorrhagic cystitis. Previous reports highlight that urinary tract involvement often precedes hepatobiliary manifestations and may serve as a key diagnostic clue to systemic ketamine toxicity [<xref ref-type="bibr" rid="REF3">3</xref>,<xref ref-type="bibr" rid="REF6">6</xref>,<xref ref-type="bibr" rid="REF12">12</xref>]. The presence of chronic cystitis with confirmatory cystoscopic and histological findings strongly supports ketamine exposure as the unifying pathogenic mechanism, a feature absent in PSC.</p><p>The pathophysiology of KIC remains incompletely understood. Proposed mechanisms include direct biliary epithelial toxicity from ketamine metabolites excreted in bile, NMDA receptor-mediated smooth muscle dysfunction leading to bile stasis, and ischemic injury related to vasoconstriction [<xref ref-type="bibr" rid="REF5">5</xref>-<xref ref-type="bibr" rid="REF7">7</xref>]. Variability in disease progression reported in the literature may reflect differences in duration, dose, and patterns of ketamine use, as well as delays in diagnosis and cessation [<xref ref-type="bibr" rid="REF12">12</xref>].</p><p>Importantly, several studies have demonstrated partial or complete biochemical improvement following ketamine abstinence, particularly when cessation occurs early in the disease course [<xref ref-type="bibr" rid="REF6">6</xref>,<xref ref-type="bibr" rid="REF12">12</xref>]. Our patient similarly showed significant biochemical recovery following strict abstinence, reinforcing published evidence that ketamine cessation remains the cornerstone of management and may prevent progression to irreversible biliary fibrosis or cirrhosis.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>KIC is an emerging cause of secondary sclerosing cholangitis that closely mimics PSC. A thorough drug history, exclusion of autoimmune and infectious causes, and recognition of associated ketamine-induced cystitis are critical for diagnosis. Early identification and strict ketamine cessation are essential, as timely withdrawal may lead to biochemical improvement and prevent progression to irreversible biliary fibrosis.</p></sec></body><back><fn-group content-type="conflict"><title>Disclosures</title><fn fn-type="COI-statement"><p><bold>Human subjects:</bold> Informed consent for treatment and open access publication was obtained or waived by all participants in this study.</p><p><bold>Conflicts of interest:</bold> In compliance with the ICMJE uniform disclosure form, all authors declare the following:</p><p><bold>Payment/services info:</bold> All authors have declared that no financial support was received from any organization for the submitted work.</p><p><bold>Financial relationships:</bold> All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work.</p><p><bold>Other relationships:</bold> All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.</p></fn></fn-group><fn-group content-type="other"><title>Author Contributions</title><fn fn-type="other"><p><bold>Concept and design:</bold>  Waqas Ahmed , Kamran Nazir, Salman Rafi, Adeel Ahmad, Asim Khaleeq</p><p><bold>Acquisition, analysis, or interpretation of data:</bold>  Waqas Ahmed , Kamran Nazir, Salman Rafi, Adeel Ahmad, Asim Khaleeq</p><p><bold>Drafting of the manuscript:</bold>  Waqas Ahmed , Kamran Nazir, Salman Rafi, Adeel Ahmad, Asim Khaleeq</p><p><bold>Critical review of the manuscript for important intellectual content:</bold>  Waqas Ahmed , Kamran Nazir, Salman Rafi, Adeel Ahmad, Asim Khaleeq</p><p><bold>Supervision:</bold>  Kamran Nazir</p></fn></fn-group><ref-list><title>References</title><ref id="REF1"><label>1</label><element-citation publication-type="journal"><article-title>Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms</article-title><source>Pharmacol Rev</source><person-group>
<name name-style="western"><surname>Zanos</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Moaddel</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Morris</surname><given-names>PJ</given-names></name>
<etal/>
</person-group><fpage>621</fpage><lpage>660</lpage><volume>70</volume><year>2018</year><pub-id pub-id-type="pmid">29945898</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1124/pr.117.015198</pub-id><pub-id pub-id-type="pmcid">PMC6020109</pub-id></element-citation></ref><ref id="REF2"><label>2</label><element-citation publication-type="journal"><article-title>Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes</article-title><source>Drug Metab Dispos</source><person-group>
<name name-style="western"><surname>Hijazi</surname><given-names>Y</given-names></name>
<name name-style="western"><surname>Boulieu</surname><given-names>R</given-names></name>
</person-group><fpage>853</fpage><lpage>858</lpage><volume>30</volume><year>2002</year><pub-id pub-id-type="pmid">12065445</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1124/dmd.30.7.853</pub-id></element-citation></ref><ref id="REF3"><label>3</label><element-citation publication-type="journal"><article-title>Liver injury is common among chronic abusers of ketamine</article-title><source>Clin Gastroenterol Hepatol</source><person-group>
<name name-style="western"><surname>Wong</surname><given-names>GL</given-names></name>
<name name-style="western"><surname>Tam</surname><given-names>YH</given-names></name>
<name name-style="western"><surname>Ng</surname><given-names>CF</given-names></name>
<etal/>
</person-group><fpage>1759</fpage><lpage>1762</lpage><volume>12</volume><year>2014</year><pub-id pub-id-type="pmid">24534547</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/j.cgh.2014.01.041</pub-id></element-citation></ref><ref id="REF4"><label>4</label><element-citation publication-type="journal"><article-title>Ketamine-induced cholangiopathy: a case report</article-title><source>Am J Gastroenterol</source><person-group>
<name name-style="western"><surname>Seto</surname><given-names>WK</given-names></name>
<name name-style="western"><surname>Ng</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Chan</surname><given-names>P</given-names></name>
<etal/>
</person-group><fpage>1004</fpage><lpage>1005</lpage><volume>106</volume><year>2011</year><pub-id pub-id-type="pmid">21540907</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1038/ajg.2010.485</pub-id></element-citation></ref><ref id="REF5"><label>5</label><element-citation publication-type="journal"><article-title>Risks associated with misuse of ketamine as a rapid-acting antidepressant</article-title><source>Neurosci Bull</source><person-group>
<name name-style="western"><surname>Zhu</surname><given-names>W</given-names></name>
<name name-style="western"><surname>Ding</surname><given-names>Z</given-names></name>
<name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name>
<name name-style="western"><surname>Shi</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Hashimoto</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Lu</surname><given-names>L</given-names></name>
</person-group><fpage>557</fpage><lpage>564</lpage><volume>32</volume><year>2016</year><pub-id pub-id-type="pmid">27878517</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1007/s12264-016-0081-2</pub-id><pub-id pub-id-type="pmcid">PMC5567488</pub-id></element-citation></ref><ref id="REF6"><label>6</label><element-citation publication-type="journal"><article-title>Repeated or continuous medically supervised ketamine administration associated with hepatobiliary adverse events: a retrospective case series</article-title><source>Drug Saf</source><person-group>
<name name-style="western"><surname>Cotter</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Wong</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Gada</surname><given-names>N</given-names></name>
<etal/>
</person-group><fpage>1365</fpage><lpage>1374</lpage><volume>44</volume><year>2021</year><pub-id pub-id-type="pmid">34699023</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1007/s40264-021-01120-9</pub-id><pub-id pub-id-type="pmcid">PMC8546385</pub-id></element-citation></ref><ref id="REF7"><label>7</label><element-citation publication-type="journal"><article-title>Microinjection of glutamate into dorsal motor nucleus of the vagus excites gallbladder motility through NMDA receptor - nitric oxide - cGMP pathway</article-title><source>Neurogastroenterol Motil</source><person-group>
<name name-style="western"><surname>Liu</surname><given-names>CY</given-names></name>
<name name-style="western"><surname>Xie</surname><given-names>DP</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>JZ</given-names></name>
</person-group><fpage>347</fpage><lpage>353</lpage><volume>16</volume><year>2004</year><pub-id pub-id-type="pmid">15198657</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1111/j.1365-2982.2004.00525.x</pub-id></element-citation></ref><ref id="REF8"><label>8</label><element-citation publication-type="book"><article-title>Ketamine</article-title><source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source><publisher-loc>Bethesda (MD)</publisher-loc><publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name><year>2012</year><uri xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK548337/" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.ncbi.nlm.nih.gov/books/NBK548337/</uri></element-citation></ref><ref id="REF9"><label>9</label><element-citation publication-type="journal"><article-title>Features of biliary tract diseases in ketamine abusers: a systematic review of case reports</article-title><source>J Med Case Rep</source><person-group>
<name name-style="western"><surname>Teymouri</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Nasoori</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Fakheri</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Nasiri</surname><given-names>A</given-names></name>
</person-group><fpage>84</fpage><volume>18</volume><year>2024</year><pub-id pub-id-type="pmid">38431685</pub-id><pub-id assigning-authority="pmc" pub-id-type="doi">10.1186/s13256-024-04421-6</pub-id><pub-id pub-id-type="pmcid">PMC10909254</pub-id></element-citation></ref><ref id="REF10"><label>10</label><element-citation publication-type="journal"><article-title>A case series of recreational ketamine-induced cholangiopathy</article-title><source>Ann Intern Med Clin Cases</source><person-group>
<name name-style="western"><surname>Garkusha</surname><given-names>LK</given-names></name>
<name name-style="western"><surname>Lin</surname><given-names>Z</given-names></name>
<name name-style="western"><surname>Lee</surname><given-names>LA</given-names></name>
</person-group><volume>3</volume><year>2024</year></element-citation></ref><ref id="REF11"><label>11</label><element-citation publication-type="journal"><article-title>Rare case of severe cholangiopathy following critical illness</article-title><source>BMJ Case Rep</source><person-group>
<name name-style="western"><surname>Patel</surname><given-names>KV</given-names></name>
<name name-style="western"><surname>Zaman</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Chang</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Wilkinson</surname><given-names>M</given-names></name>
</person-group><volume>2014</volume><year>2014</year><pub-id assigning-authority="pmc" pub-id-type="doi">10.1136/bcr-2013-202476</pub-id><pub-id pub-id-type="pmcid">PMC4180570</pub-id><pub-id pub-id-type="pmid">25270153</pub-id></element-citation></ref><ref id="REF12"><label>12</label><element-citation publication-type="journal"><article-title>Ketamine cholangiopathy: largest UK single-centre case series reporting clinical outcomes in 36 patients</article-title><source>Gut</source><person-group>
<name name-style="western"><surname>Arms-Williams</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Perkins</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Wiles</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Moore</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Richardson</surname><given-names>P</given-names></name>
</person-group><year>2025</year></element-citation></ref></ref-list></back></article>